Health
Pfizer’s Coronavirus Vaccine Candidate Shows Promise in Early Trial – Myhealthyclick
A coronavirus vaccine candidate developed by Pfizer has shown promising results in Phase I/II clinical trials. The experimental vaccine based on a genetic code called messenger RNA has been found effective at sparking a strong immune response, preventing COVI…
Pfizers experimental coronavirus vaccine, which is based on
RNA gene technology, has shown promising results in an early trial.
According to a news release from the journal Nature, the vaccine
candidate, called BNT162b1, elicited a robust immune response in participants,
which increased with dose level and with a second dose.
Dr. Judith Absalon of Pfizer, who led the early clinical
phase I/II trial, said BNT162b1 is based on messenger RNA, a genetic code that
helps kick-start the immune r…
-
Noosa News18 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News17 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General21 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News20 hours agoStar Entertainment faces $36.5m blow if Queen’s Wharf deal flops